Achillion Pharmaceuticals, Inc.  

(Public, NASDAQ:ACHN)   Watch this stock  
Find more results for ACHN
8.28
+0.01 (0.12%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.14 - 8.37
52 week 5.57 - 10.95
Open 8.18
Vol / Avg. 1.42M/1.39M
Mkt cap 1.11B
P/E     -
Div/yield     -
EPS -0.07
Shares 136.64M
Beta 2.26
Inst. own 86%
Aug 4, 2016
Q2 2016 Achillion Pharmaceuticals Inc Earnings Release - Tentative - 9:30AM EDT - Add to calendar
Jul 13, 2016
Achillion Pharmaceuticals Inc at Cantor Fitzgerald Healthcare Conference - Webcast
Jun 22, 2016
Achillion Pharmaceuticals Inc at JMP Securities Life Sciences Conference
Jun 14, 2016
Achillion Pharmaceuticals Inc at William Blair Growth Stock Conference
Jun 7, 2016
Achillion Pharmaceuticals Inc at Jefferies Healthcare Conference
Jun 1, 2016
Achillion Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
May 25, 2016
Achillion Pharmaceuticals Inc Annual Shareholders Meeting
May 5, 2016
Achillion Pharmaceuticals Inc at Deutsche Bank Health Care Conference
May 3, 2016
Q1 2016 Achillion Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -7.61%
Operating margin - -22.85%
EBITD margin - -21.80%
Return on average assets -15.86% -1.62%
Return on average equity -16.37% -1.70%
Employees 79 -
CDP Score - -

Address

300 George St
NEW HAVEN, CT 06511-6624
United States - Map
+1-203-6247000 (Phone)
+1-203-6247003 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.

Officers and directors

David I. Scheer Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Milind S. Deshpande Ph.D. President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Mary Kay Fenton CPA Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Joel C. Barrish Ph.D. Executive Vice President, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Martha E. Manning Esq. Executive Vice President, General Counsel, Corporate Secretary
Age: 61
Bio & Compensation  - Reuters
David Apelian M.D. Ph.D. Executive Vice President, Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Joseph Truitt Executive Vice President, Chief Commercial Officer
Age: 51
Bio & Compensation  - Reuters
Amy Jennings Senior Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Michael D. Kishbauch Director
Age: 66
Bio & Compensation  - Reuters
Frank A. G. M. Verwiel M.D. Director
Age: 54
Bio & Compensation  - Reuters